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Abstract
Real-time visualizations of drug
pharmacokinetics and pharmacodynamics may help
anesthesiologists more accurately titrate intravenous
anesthetics for sedation and analgesia in a critical
care setting. To assess synergism between propofol
and opioids, our laboratory has developed response
surface pharmacodynamic interaction models for
remifentanil and propofol. These models use
surrogate measures of analgesia and sedation from a
volunteer study but must be validated before they are
applied to patients in a real-time display; the
surrogate measures used in the volunteer study must
be related to clinical patient responses. The aim of
this study is to explore the pharmacodynamic
relationship between the surrogate and clinical
responses. We hypothesize that the surrogate stimuli
from the volunteer study can be mapped to surgical
stimuli; we expect the levels of anesthesia required to
moderate responses to the surrogate measures relate
to levels of sedation and analgesia needed to prevent
responses to surgical stimuli in the operating room.
Introduction
During the development of an anesthetic,
considerable resources are used to create
pharmacokinetic profiles. Simply put,
pharmacokinetics describe what the body does to the
drug; pharmacokinetic models give the concentration
ofthe drug in the body as a function of time. Once
the drug is administered, it is transported in the blood
to different body tissues, in particular the biophase or
effect site. The biophase consists of the specific
tissues, membranes, receptors, and enzymes where
the drug exerts its pharmacologic effect; the central
nervous system is the biophase for anesthetics. The
concentration of anesthetics at the effect site can be
predicted using pharmacokinetic models. 1
Our lab developed a computer simulation
that visualizes the pharmacokinetics of rernifentanil
and propofol, two, commonly used, intravenous
anesthetics. (See Figure 1.) Anesthesiologist study
subjects were asked to maintain a target therapeutic

drug concentration and stable hemodynamics in a
simulated patient by directing drug administrations.
Subjects who were shown the display more closely
maintained the target concentration and had shorter
periods of inadequate anesthesia than subjects who
only used traditional anesthesia monitors. The results
suggest that the visualization of pharmacokinetic
models may assist in clinical decision-making. 2
However, anesthesiologists typically are worried less
about the drug concentrations than they are about the
drug effects on their patients.

Figure 1. Screen shot of computer visualization of
anesthesia pharmacokinetics, 20 minutes in the past to 10
minutes in the future. The colored vertical bars represent
drug boluses.

Pharmacodynamic models can be defmed as
what the drug does to the body; pharmacodynamics
describe the drug effects as functions of the drug
concentrations at the effect site. Pharmacodynamic
models are typically sigmoidal in shape for
anesthetics. (See Figure 2.) The midpoint of the
curve is called the EC50 value, and is the effect-site
concentration at which there is a 50% probability that
the patient is adequately anesthetized. I
Anesthesiologists generally target the EC95 value
such that there is a 95% probability that their patients
will not respond to stimuli. Together,
pharmacokinetic and pharmacodynamic models
describe the rate of onset of a drug and the expected
duration of drug effect. However, anesthesia is
generally provided using several drugs in
combination.
When more than one anesthetic is used,
there are several possible drug interactions. (See
Figure 3.) The axes concentrations of Drug A and
Drug B and the lines indicate an equal level of
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Figure 2. Sigmoidal shape of a typical pharmacodynamic
function for a single drug.

anesthetic effect, called an isobole. When the isobole
bows towards the origin, the drugs are synergistic,
such that the drugs given in combination reduces the
total amount of drug needed to provide a target effect
level. A straight line suggests that the drugs are
additive, meaning that there is no interaction between
them. Ifthe isobole bows away from the origin, then
the relation is infraadditive or antagonistic, such that
the higher the concentration of one drug, the greater
the concentration of the other drug to maintain the
effect level. When a full range of drug effect, instead
of a single isobole, is represented, a response surface
is created.

site concentrations in a non-surgical volunteer study.
At several propofol-remifentanil concentration pairs,
noxious stimuli, surrogates for surgical stimuli, were
applied to the volunteers. The surrogate measures
were assessment of the subject's alertness (using the
OAA/S scale), laryngoscopy, electrical tetany, and
pressure algometry. The response surfaces for these
four surrogates showed significant synergism
between remifentanil and propofol. 3 ,4 The surfaces
for sedation and for laryngoscopy are shown in
Figure 4. Other studies have shown fentanyl
cogeners to have related pharmacodynamic effects
that might be related to one another using a scaling
factor. 5 Because remifentanil is a fentanyl derivative,
it is believed that the response surface for propofol
and remifentanil may actually model propofol-opioid
pharmacodynamic interactions by using different
scaling factors for each opioid.
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surrogate stimuli (the sedation or OAAlS surface is above,
the surface for laryngoscopy below). Note that much higher

Figure 3. Isoboles represent pharmacodynamic interactions

levels of drug are needed to provide sufficient analgesia for

that exert the same drug effect for two drugs in combination .

laryngoscopy compared to simply sedating a patient. Also

Our lab has created response surfaces for
propofol and remifentanil that describe the drug
effect for clinical propofol and remifentanil effect-

note the synergism between propofol and remifentanil.

Methods
Data Collection
With institutional review board approval
from the University Hospital and informed consent,
we studied 16 patients (6 males and 10 females) ages
25 to 64 scheduled for abdominallaparoscopic
surgery under total intravenous anesthesia. 13
patients received midazolam (1.5 mg) as a sedative
before entering the operating room (OR). The
infusion rates of propofol and of remifentanil were
digitally acquired. Drug boluses were recorded by
hand. Patient hemodynamics (non-invasive blood
pressure and heart rate) and bispectral index (BJS)
were also acquired digitally.
The times at loss of consciousness (LaC)
and recovery of consciousness (ROC) were recorded.
The adequacy or inadequacy of the anesthetic
(indicated by movement or a 20% increase in
baseline heart rate) was observed at selected
milestones of the surgery (i.e. laryngoscopy and
intubation, skin incision, trocar placement, intraabdominal manipulation, wound closure, and skin
closure). To ensure that a rise in heart rate was
indicative of a new painful stimulus, the "baseline
heart rate" was the average heart rate over the past
10-15 minutes.
At the end of surgery, the patient was
followed into the post-anesthetic care unit (PACU).
The patient's alertness was scored using the
observer's assessment of awareness and sedation
(OANS) once every 5 minutes for a total time ono
minutes. (A subject in a deep sleep receives a score
of 1 and a score of 5 indicates that the subject is
alert.) During this time the patient rated the
perceived pain (resulting from the surgery) on a scale
of 0-10 (0 being absolutely no pain, 10 being the
greatest pain ever experienced). The drug doses were
also recorded.
Pharmacokinetic Validation
Before validating the pharmacodynamic
models, we validated that the effect-site drug
concentrations predicted by our program are accurate.
Predictions from our computer program were
compared to those of ST ANPUMP, another research
pharmacokinetic simulator. (ST ANPUMP is freely
available from the author, Steven L. Shafer, MD,
Anesthesiology Service (II2A), PA VAMC, 3801
Miranda Ave., Palo Alto, CA 94304.) We used the
Marsh model, based on the Gepts model, for
propofol, the Minto, Schnider model for remifentanil,
and the Shafer, Varvel, Aziz, and Scott model for
fentany1.6,7,8 Because the pharmacodynamic response

surfaces are functions of propofol and remifentanil
(an opioid), only the simulation scenarios shown in
Table 1 were compared.
Table 1: Pharmacokinetic Simulation Scenarios
for Prediction Comparison
Anesthetic
Administration
Dose
Propofol
Bolus
100mg
Propofol
Infusion
100 J.lg /kg/min
Remifentanil
Bolus
250 J.lg
Remifentanil
Infusion
.20 J.lg /kg/min
Fentanyl
Bolus
200 J.lg
Pharmacodynamic Validation
To validate the pharmacodynamic models,
responses (and non-responses) of patients to surgical
stimuli were compared to the model predictions. To
visualize relationships between responses to surgical
stimuli versus surrogate measures, the predicted
anesthetic concentrations at the surgical stimuli were
plotted on the pharmacodynamic response surfaces
from the volunteer study.

Comparison between the pharmacokinetic
simulations showed that our implementations of the
kinetic models match published models. The results
of the pharmacokinetic simulations for boluses are
shown in Figure 5. The infusion simulations showed
even fewer differences. The model parameters were
loaded externally into STANPUMP, as the internal
models were modifications of published models. It is
also significant to note the challenge of modeling
rapidly changing drug concentrations, such as occur
when a bolus is administered.
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Figure 4. Comparisons between pharmacokinetic model
implementations (our simulations and those of STAN PUMP)
for propofol (the two highest curves), fentanyl (the middle
curves that are visually indistinguishable), and remifentanil
(the lowest curves, also indistinguishable).

Figure 5 contains top-down or topographical
views of the propofol-remifentanil pharmacodynamic
response surfaces with EC50 and EC95 isoboles.
Data points are the predicted concentration pairs of
propofol and remifentanil at selected clinical events.
X's represent responses while O's represent no
response on the laryngoscopy and electrical tetany
surfaces. Diamonds on the sedation surface represent
patient recovery of consciousness. For laryngoscopy,
2 of 5 responses and 5 of 7 non-responses were
accurately predicted by the model EC95 isobole. For
skin incision, we observed no responses and 19 of 31
non-responses were accurately predicted by the
model EC95 isobole. For recovery of consciousness,
6 of 11 wake-ups followed the model EC95
prediction EC95.
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The preliminary data set indicates that the electrical
tetany and OAAJS response surfaces correlate to skin
incision and recovery of consciousness, respectively.
The lack of intraoperative responses presents a
challenge for validating the response surfaces. It is
hoped that data from the PACU will include patient
responses to pain as the anesthetic effect-site
concentrations decrease. Complete validation and the
necessary adaptation ofthe PD models will require a
larger sample size. To extend the models' clinical
relevance, PD interactions between more anesthetics
(IV and volatile) are needed.
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